

*THE EFFECT OF DUAL THERAPY OF  
PEGYLATED INTERFERON AND  
RIBAVIRIN ON VIRAL LOAD AND LIVER  
ENZYMES OF HEPATITIS C PATIENTS*

**Thesis for Fulfillment of Master Degree**

**Presented by**

Dr. Mohamed Ahmed Abdullah

**Supervised by**

Prof. Dr. Mona Mahmoud Ezzat

**Professor of medical Microbiology and Immunology  
Faculty of Medicine – Cairo University**

Dr. Eman Ahmed El-Seidi

**Assist. Professor of medical Microbiology and Immunology  
Faculty of Medicine – Cairo University**

**2009**

بسم الله الرحمن الرحيم

"رب أوزعني أن أشكر نعمتك التي أنعمت  
علي وعلى والدي وأن أعمل صالحا ترضاه  
وأدخلني برحمتك في عبادك الصالحين"

صدق الله العظيم

(سورة الأحقاف، آية ١٥ )

---

### **Dedication**

To my wife **NADA**, for her support and effort allover my career.

To my **Father, Mother and my family**, for their praying and help allover my life.

Before them all for my son **KAREEM**, who is shinning my life.

---

## **Abstract**

Chronic hepatitis C infection is recognized as an important health problem worldwide. Approximately 2–3% of the world population is infected with hepatitis C virus (HCV). Egypt has the highest seroprevalence for Hepatitis C, up to 20% in some areas.

Hepatitis C is caused by a small, single-stranded RNA virus. The virus replicates in the liver at a high rate, resulting in average serum HCV RNA levels of 1 to 2 million genome equivalents per milliliter.

Although some patients with acute HCV infection have an immune response sufficient to clear the virus, chronic infection develops in 55 to 85% of patients. Once established, chronic infection rarely resolves spontaneously. The hepatocellular injury seen in chronic HCV disease appears to be due not to a direct cytopathic effect of the virus but rather to an immunologically mediated injury, with natural killer cells and CD8+ T cells playing a central role.

The currently recommended therapy for chronic hepatitis C is a combination of formulations of interferon alfa and ribavirin.

### **Key Words:**

**HCV, Diagnosis of HCV, Treatment and prognosis**

---

## **Acknowledgment**

*First & foremost of all, my deepest gratitude and thanks to Allah, by the grace of whom this work was possible.*

*I Would like to express my sincere thanks and my gratefulness to **Prof. Dr. Mona M. Ezzat**, Professor of Medical Microbiology and immunology, Faculty of Medicine, Cairo university for her kind supervision, Valuable advice, fruitful discussions, continuous support and encouragement throughout this work.*

*I would like to acknowledge with deep gratitude **Dr. Eman A. El-SEIDI**, Assistant Professor of medical Microbiology and immunology, Microbiology Department, Faculty of Medicine, Cairo University for her continuous guidance & supervision, encouragement, advice, Valuable remarks and facilities offered to accomplish this work.*

*I am also taking this opportunity to thank all staff members of the microbiology Department at Cairo University, for their sincere cooperation.*

*Special thanks to **Dr. Aly abd-elsattar**, head of virology department - central labs – ministry of health, for his endless support and help.*

---

*Thanks for all the staff members of virology department - central labs – ministry of health, for their help.*

*Words will never be able to express my deepest gratitude to all those who helped me to make this work possible*

---

## CONTENTS

<i>Subject</i>	<i>Page</i>
<i>Introduction &amp; Aim of work</i>	<i>1</i>
<i>Review of Literature</i>	
<i><u>HCV</u></i>	<i>4</i>
<i>History</i>	<i>4</i>
<i>Flaviviridae</i>	<i>5</i>
<i>Structure of HCV</i>	<i>6</i>
<i>Genome</i>	<i>10</i>
<i>Replication</i>	<i>12</i>
<i>Epidemiology</i>	<i>13</i>
<i>Transmission</i>	<i>14</i>
<i>Methods of transmission</i>	<i>17</i>
<i>Signs and symptoms</i>	<i>19</i>
<i>Prevention</i>	<i>19</i>
<i><u>Diagnosis of HCV</u></i>	<i>21</i>
<i>Laboratory diagnosis</i>	<i>22</i>
<i>EIA</i>	<i>22</i>
<i>RIBA</i>	<i>23</i>
<i>Nucleic acid testing for HCV</i>	<i>25</i>
<i>Liver biopsy</i>	<i>29</i>
<i>Non- specific measures</i>	<i>30</i>

---

<i><u>Treatment and prognosis</u></i>	36
<i>Interferon</i>	38
<i>Types of interferon</i>	39
<i>Mechanism of action</i>	40
<i>Pharmaceutical uses</i>	44
<i>Route of administration</i>	45
<i>Adverse effects</i>	46
<i>Ribavirin</i>	48
<i>History</i>	48
<i>Mechanism of action</i>	49
<i>Adverse effects</i>	50
<i>Ribavirin derivatives</i>	51
<i>New directions in HCV therapy</i>	52
<i>Introduction</i>	52
<i>New interferon preparations</i>	53
<i>Ribavirin – like drugs</i>	54
<i>Vaccinations</i>	59



---

<i>Materials and Methods</i>	60
<i>Selection criteria of patients</i>	60
<i>Sample collection and preparation</i>	60
<i>Scheme of laboratory work</i>	60
<i>Elisa anti- HCV IgG</i>	61
<i>SGOT and SGPT</i>	64
<i>Real- time PCR</i>	65
<i>Statistical analysis</i>	68
<i>Results</i>	69
<i>Discussion</i>	81
<i>Conclusion &amp; Recommendations</i>	87- 88
<i>Summary</i>	89
<i>References</i>	91
<i>Arabic summary</i>	106

---

## **LIST OF ABBREVIATIONS**

<b>1</b>	<b>ARF</b>	Alternative Reading Frame
<b>2</b>	<b>ARFP</b>	Alternate Reading Frame Protein
<b>3</b>	<b>CPHL</b>	Central Public Health Laboratories
<b>4</b>	<b>EOT</b>	End of Treatment
<b>5</b>	<b>EVR</b>	Early Virological Response
<b>6</b>	<b>Hrp</b>	Horseradish Peroxidase
<b>7</b>	<b>IFNAR</b>	IFN- $\alpha$ Receptor
<b>8</b>	<b>IFNs</b>	Interferons
<b>9</b>	<b>IRES</b>	Internal Ribosome Entry Site
<b>10</b>	<b>ISDR</b>	Interferon Sensitivity Determining Region
<b>11</b>	<b>ISGF3</b>	Interferon Stimulate Transcription Factor-3
<b>12</b>	<b>JAK</b>	The Janus Kinase
<b>13</b>	<b>JEV</b>	Japanese Encephalitis Virus
<b>14</b>	<b>LFTs</b>	Liver Function Tests
<b>15</b>	<b>MPGN</b>	Membranoproliferative Glomerulonephritis
<b>16</b>	<b>NANBH</b>	Non-A Non-B Hepatitis
<b>17</b>	<b>NAT</b>	Nucleic Acid Testing
<b>18</b>	<b>NCR</b>	Noncoding Region
<b>19</b>	<b>NS</b>	Non-Structural
<b>20</b>	<b>OD</b>	Optical Density
<b>21</b>	<b>PKR</b>	Protein Kinase R
<b>22</b>	<b>QRT</b>	Quantitative Real Time
<b>23</b>	<b>RT-PCR</b>	Reverse Transcriptase PCR
<b>24</b>	<b>RT-PCR</b>	Real Time PCR
<b>25</b>	<b>s/co</b>	Sample / Cut Off
<b>26</b>	<b>SR-BI</b>	Scavenger Receptor Class B1
<b>27</b>	<b>STAT</b>	Signal Transducer and Activator of Transcription
<b>28</b>	<b>SVR</b>	Sustained Virological Response
<b>29</b>	<b>TLR 3</b>	Toll Like Receptor 3
<b>30</b>	<b>TMA</b>	Transcription-Mediated Amplification
<b>31</b>	<b>TMB</b>	Tetramethylbenzidine

---

## **LIST OF TABLES**

<b>Number</b>	<b>Table</b>	<b>Page</b>
<b>A</b>	Tests for HCV infection	21
<b>B</b>	Pharmaceutical forms of interferons (Genetic & trade names)	47
<b>C</b>	ELISA assay scheme of ADALTIS kit	62
<b>D</b>	interpretation of the ELISA results	63
<b>E</b>	Real- Time PCR Master Mix Reagents (Applied Biosystems, USA).	67
<b>F</b>	The thermal profile of Real-Time PCR	68
<b>G</b>	The reference values of positive controls in Real-Time PCR.	68
<b>1</b>	Viral load before treatment in relation to sex	70
<b>2</b>	End of treatment response (after 24 weeks) according to sex	71
<b>3</b>	Viral load in relation to response to treatment after 12 weeks	71
<b>4</b>	Viral load before treatment among cases in relation to EOT virological response	72
<b>5</b>	Levels of liver enzymes before treatment and after 24 weeks of treatment	72
<b>6</b>	Liver enzymes (before & after treatment) in relation to EOT virological response	73

---

## **LIST OF FIGURES**

<b>Number</b>	<b>Figure</b>	<b>Page</b>
<b>A</b>	Structure of the hepatitis C virus particle	5
<b>B</b>	Electron micrograph of HCV	6
<b>C</b>	Genome organization of hepatitis C virus	6
<b>D</b>	A simplified diagram of the HCV replication cycle	10
<b>E</b>	Sources of infection in the US	13
<b>F</b>	Cirrhosis of the liver and liver cancer may ensue from hepatitis C	19
<b>G</b>	Steps of Indirect ELISA	23
<b>H</b>	Hepatitis C virus infection testing in asymptomatic persons	24
<b>I</b>	Alanine transaminase	31
<b>J</b>	Aspartate aminotransferase	32
<b>K</b>	The relation between alanine transaminase and Anti-HCV antibody in hepatitis C patients	32
<b>L</b>	The effect of PEG alone Vs. IFN + RBV vs. PEG + RBV	37
<b>M</b>	The effect of IFN vs. pegylated IFN	41
<b>N</b>	Vials filled with human leukocyte interferon	44
<b>1</b>	Schematic representation of treatment and follow-up of patients included in the study	69
<b>2</b>	Mean and standard deviation of viral load before treatment in relation to sex	70
<b>3</b>	Mean levels of SGOT and SGPT before and after treatment	73
<b>4</b>	Correlation between viral load before treatment and SGPT	74
<b>5</b>	Correlation between viral load before treatment and SGOT	75
<b>6</b>	Amplification curves of some positive samples	76
<b>7</b>	Amplification curves of 8 samples	77
<b>8</b>	Amplification curves of positive controls used as quality measures in the PCR run	78
<b>9</b>	A standard curve made by use of three positive controls with known standard quantities	79
<b>10</b>	The standard curve with measuring the quantity of samples on the curve	80

---

## **INTRODUCTION**

Chronic hepatitis C infection is recognized as an important health problem. Approximately 2–3% of the world population is infected with hepatitis C virus (HCV). HCV is one of the leading causes of liver failure and cancer, and the single most common indication for liver transplantation (*Rosen and Martin, 2000*).

Egypt has the highest seroprevalence for Hepatitis C, up to 20% in some areas. There is a hypothesis that the high prevalence is linked to a now-discontinued mass-treatment campaign for schistosomiasis, which is endemic in Egypt (*Frank et al., 2000*). Regardless of how the epidemic started, a high rate of HCV transmission continues in Egypt, both iatrogenically, within the community and household (*Thomas and Seeff, 2005*).

Hepatitis C is often clinically silent. Symptoms of jaundice develop in only one third of patients with acute infection, and most patients with chronic infection have few if any clinical manifestations, at least until cirrhosis is present. The natural history of hepatitis C is variable; cirrhosis eventuates in 20 to 30% of patients with chronic infection, generally after 2 to 3 decades (*Thomas et al., 2005*). Once cirrhosis evolves, hepatocellular carcinoma develops in 1 to 4% of these patients per year (*Fattovich et al., 2004*).

Hepatitis C is primarily a blood-borne or parenterally transmitted infection. Vehicles and routes of parenteral transmission include contaminated blood and blood products, needle sharing, contaminated instruments (e.g., in hemodialysis, reuse of contaminated medical devices, tattooing devices, acupuncture needles, razors and manicure devices), occupational and nosocomial exposures such as needle stick injuries (*Henderson, 2003*).

Hepatitis C is caused by a small, single-stranded RNA virus (*Lauer and Walker, 2001 and Lindenbach and Rice, 2005*). The virus replicates in the liver at a high rate, resulting in average serum HCV RNA levels of 1 to 2 million genome equivalents per milliliter (*Neumann et al., 1998*). The six genotypes of HCV vary in nucleotide sequence by 30 to 50% (*Simmonds et al., 2005*). In the Middle East, almost all anti-HCV-positive individuals identified on blood donor screening are infected with genotype 4 (*Simmonds et al., 1993*).

---

---

Although some patients with acute HCV infection have an immune response sufficient to clear the virus, chronic infection (defined as detectable HCV RNA for more than 6 months) develops in 55 to 85% of patients (*Hoofnagle et al., 2002*).

The currently recommended therapy for chronic hepatitis C is a combination of formulations of interferon alpha and ribavirin (*Strader et al., 2004*). Interferon alpha is a cytokine that has an important function in the innate antiviral immune response (*Feld and Hoofnagle, 2005*). Interferon alpha also induces the expression of genes involved in the immune response, resulting in activation of natural killer cells, maturation of dendritic cells, proliferation of memory T cells, and prevention of T-cell apoptosis (*Tilg et al., 1997*).

Ribavirin is an oral nucleoside analogue with broad activity against viral pathogens (*Feld and Hoofnagle, 2005*). Its mechanism of action against HCV is not completely clear. Ribavirin appears to have minimal direct activity against HCV replication (*Lau et al., 2002*), but it may lead to rapid and lethal mutation of virions or depletion of intracellular guanosine triphosphate, which is necessary for viral RNA synthesis (*Crotty et al., 2000 and Maag et al., 2001*). Ribavirin also has immune modulatory effects (*Lau et al., 2002*).

Interferon alpha was approved as a therapy for hepatitis C in 1991. However, the overall rate of sustained virologic response, defined as the absence of HCV RNA in serum at least 6 months after the discontinuation of therapy, was low (generally <20%) with interferon alpha monotherapy (*Myers et al., 2002*). The subsequent addition of the oral antiviral agent ribavirin to interferon led to a marked improvement in rates of sustained virologic response (40 to 45%) (*McHutchison et al., 1998 and Poynard et al., 1998*). Ribavirin alone lowered serum enzyme levels but had little effect on HCV RNA levels (*Brok et al., 2006*).

The most recent important advance in the treatment of hepatitis C was the development of a long-acting interferon, pegylated interferon (peg interferon), produced by the covalent attachment of polyethylene glycol to the interferon molecule. With its increased half-life, peg interferon can be given as a weekly dose (*Glue et al., 2005*). Two peg interferon formulations are currently approved for the treatment of hepatitis C: alfa-2a and alfa-2b. In two large trials of these agents, the rates of sustained virologic response to a 48-week course of peg interferon and ribavirin were 54 and 56%, as compared with 44 and 47%

---

---

with standard interferon and ribavirin and only 29% with peg interferon alone (*Manns et al., 2001 and Fried et al., 2002*).

Patients who achieve a SVR have a greater than 95% chance of still being virus-free 5 years later (*Swain et al., 2007*). This end point is associated with regression of fibrosis, decreased incidence of hepatocellular carcinoma, and overall reduced morbidity and mortality (*Veldt et al., 2007*).

### **Aim of the study**

The aim of this study was to assess the effect of dual treatment with pegylated interferon and ribavirin on the viral load and liver enzymes in patients with chronic HCV, in order to determine the efficacy of this combination therapy on hepatitis C patients in Egypt.